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  Background:  A reflex cough is often observed after an intravenous (IV) bolus of remifentanil. Since ketamine was reported 
to be effective in modulating the cough reflex, this prospective, randomized, double-blind, placebo-controlled study was designed 
to evaluate the efficacy of pretreatment with ketamine on remifentanil-induced cough. 
  Methods:  320 patients undergoing general anesthesia for elective surgery were randomly allocated into two groups to receive 
either IV ketamine 0.1 mg/kg (ketamine group, n = 156) or 0.9% saline (saline group, n = 154) 1 min before administration 
of remifentanil at a target effect-site concentration of 5 ng/ml. Severity of cough was graded (mild, 1−2; moderate, 3−4; and 
severe, 5 or ＞5). 
  Results:  The overall incidence of cough was significantly higher in the saline group (43/154 patients; 0.28, 95% CI 0.21, 
0.36) than that in the ketamine group (18/156 patients; 0.12, 95% CI 0.07, 0.18) (P ＜ 0.001). However, there was no significant 
difference in the severity and the onset time of cough between the groups. 
  Conclusions:  IV ketamine 0.1 mg/kg one minute before remifentanil was effective in suppressing remifentanil-induced cough 
without affecting the severity and onset time.  (Korean J Anesthesiol 2009; 56: 624～7)
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INTRODUCTION
  Remifentanil has favorable pharmacokinetic properties with 
rapid onset and offset of action, which makes it appropriate 
adjunct during anesthesia induction to provide cardiovascular 
stability and intense analgesia. However, a small dose of intra-
venous remifentanil elicits cough, as any other opioid of fen-
tanyl series [1]. Based on previous studies, the incidence of 
remifentanil-induced cough was higher than that of fentanyl-in-
duced cough [1,2]. The prevention of opioid-induced cough has 
an important clinical implication because opioid associated 
cough can be severe enough to cause multiple conjunctival and 
periorbital petechia, which may have resulted form increased 
intracranial, intra-ocular, and intra-abdominal pressure [3,4]. 
The increase in intraoculr or intracranial pressure can be dev-
astating to patients with glaucoma or a space occupying lesion 
in the brain. The need to reduce cough during opioid injection 
has encouraged many different approaches using local anes-
thetics, ketamine, selective β-agonist and many others with 
varying results [1,5-9]. 
  N-methyl-D-aspartate (NMDA) receptor was reported to play 
a critical role in the modulation of the cough reflex [10]. 
Therefore, the purpose of this study was to evaluate the effi-
cacy of pretreatment with ketamine, an NMDA receptor antag-
onist, on remifentanil-induced cough. 
MATERIALS AND METHODS
  This study was approved by the institutional review board 
and written informed consent for the study was obtained from 
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Table 1. Patients’ Characteristics and Remifentanil Dose
Ketamine
(n = 156)
Saline
(n = 154)
Sex (M/F)
Age (years)
Weight (kg)
Height (cm)
Smoker
ASA physical status (I/II)
Remifentanil dose (μg)
87/69
39.0 ± 12.9
64.6 ± 11.1
166.0 ± 8.9
47 (30.1%)
127/29
80.2 ± 6.6
83/71
37.3 ± 11.9
65.7 ± 11.2
166.9 ± 8.7
51 (33.1%)
130/24
80.8 ± 6.5
Values are mean ± SD or number of patients. 
all patients. Three hundred and twenty patients, ASA physical 
status I or II, aged 18−65 years, undergoing general anes-
thesia for elective surgery, were studied. Patients were ran-
domly allocated to either control or ketamine group using 
computer generated randomization list generated by a statis-
tician in a sealed envelope. The exclusion criteria included 
body weight exceeding 20% of the ideal body weight, a his-
tory of bronchial asthma or chronic obstructive pulmonary dis-
ease, respiratory tract infection, hypertension treated with an-
giotensin converting enzyme inhibitors, and the use of psycho-
active drugs. 
  No premedication was administered before surgery. Before 
arrival in the operating room, a 20-gauge cannula was inserted 
in the dorsum of the hand and connected to a T-connector for 
drug injection. An independent researcher prepared study sy-
ringe for each patient. Anesthesiologists were blinded to the 
patient group. On arrival in the operating room, all patients 
were monitored with electrocardiogram, pulse oximeter, non-
invasive blood pressure, and capnography. One min before re-
mifentanil administration, patients received either IV ketamine 
0.1 mg/kg (diluted with normal saline to 1 mg/ml) or equal 
volume of 0.9% saline (0.1 ml/kg) over 5 sec according to 
their group. Remifentanil was administered at a target ef-
fect-site concentration of 5 ng/ml via target-controlled infusion 
(TCI) pump (OrchestraⓇ, Fresenius Vial, France). After IV re-
mifentanil infusion, the onset time (from the start of TCI to 
the beginning of coughing) and severity of cough were ob-
served for 1 min and recorded by an observer who was blind-
ed to the type of medication given to the patients. Severity of 
coughing was graded based on the number of episodes of 
cough (mild, 1−2; moderate, 3−4; and severe, 5 or ＞5). 
Assisted mask ventilation with oxygen was applied if desatura-
tion was observed (SpO2 ＜ 90%). The incidences of apnea, 
truncal rigidity, and psychomimetic symptoms were also 
recorded. Apnea was defined as a pause in breathing for more 
than 15 seconds and truncal rigidity as increased large trunk 
muscle tone, which renders facemask ventilation difficult or 
impossible. Any unpleasant symptoms including dissociative 
feelings (“elevator” effect), alertness disturbances (somnolence 
or insomnia) or sensory changes (taste changes, numbness, tin-
gling, hot, cold) were considered as psychomimetic symptoms. 
Mean arterial pressure (MAP), heart rate (HR), and SpO2 were 
recorded on arrival in the operating room (baseline) and 1 min 
after remifentanil infusion. Authors hypothesized that the in-
cidence of cough during remifentanil injection would be re-
duced with pretreatment of an NMDA antagonist, ketamine. 
Therefore, the primary outcome was the reduction of the in-
cidence of cough and the secondary outcome was the severity 
of cough. 
  Considering the incidence of remifentanil-induced cough was 
27% [1] and assuming a decrease in the incidence of cough to 
half of control after ketamine treatment, this study required at 
least 152 patients per group at the 5% level of significance 
and 80% power of test. Considering 5% drop out rate, 320 
patients were randomized in this study. 
  Statistical analyses were performed with the statistical pack-
age (SPSS 13.0 for windows, SPSS Inc, Chicago, IL, USA). 
Data are presented as mean ± SD or number of patients. 
Patients’ characteristics, the difference of onset time to cough 
and hemodynamic variables between groups were compared 
with Student’s t-test. Incidence of coughing was analyzed with 
chi-square test. A P value ＜ 0.05 was considered statistically 
significant. 
RESULTS
  Four patients in ketamine group and 6 patients in saline 
group did not complete the study due to intravenous line 
obstruction. There was no significant difference in patient char-
acteristics between the two groups (Table 1). The overall in-
cidence of cough was significantly higher in the saline group 
(43/154 patients; 0.28, 95% CI 0.21, 0.36) than that in the keta-
mine group (18/156 patients; 0.12, 95% CI 0.07, 0.18) (P ＜ 
0.001). However, there was no significant difference in the se-
verity and the onset time of cough between the groups. In the 
ketamine group, 18 patients had cough and 10, 4, and 4 of 
those patients had mild, moderate, and severe cough, 
respectively. This was similar to the saline group in which 23, 
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Table 2. Incidence of Cough, Severity of Cough, and Onset Time after Remifentanil Infusion
Group No cough
Incidence and severity of cough 
Onset (s)
Total Mild Moderate Severe
Ketamine (n = 156)
Saline (n = 154) 
138a)/156
111/154
18/156 (11.5%)
43/154 (27.9%)
10/18 (55.5%)
23/43 (53.5%)
4/18 (22.2%)
12/43 (27.9%)
4/18 (22.2%)
8/43 (18.6%)
26.8 ± 5.7
24.3 ± 6.1
Values are number of patients or mean ± SD.  a)P ＜ 0.001 compared with saline group. 
Table 3. Mean Arterial Pressure and Heart Rate during Anesthesia 
Induction
Group Baseline
1 min after 
remifentanil 
infusion
MAP (mmHg)
HR (beats/min)
Ketamine (n = 134)
Saline (n = 140)
Ketamine (n = 134)
Saline (n = 140)
96.1 ± 13.7
98.3 ± 11.9
75.0 ± 15.0
72.3 ± 15.6
97.8 ± 12.9
94.9 ± 12.8a)
76.8 ± 17.3a)
74.1 ± 17.9a)
Values are mean ± SD.  MAP: mean arterial blood pressure, HR: 
heart rate.  a)P ＜ 0.05 compared with baseline value.
12, and 8 of 43 patients who coughed had mild, moderate, 
and severe cough, respectively (Table 2). No patient com-
plained psycomimetic symptoms in the ketamine group during 
anesthesia induction. 
  Hemodynamic data were lost in 22 and 14 patients in ket-
amine and saline group, respectively. MAP and HR during an-
esthesia induction are listed in Table 3. MAP at 1 min after 
remifentanil infusion in saline group was significantly de-
creased from the baseline value. In the both groups, HR was 
significantly increased significantly 1 min after remifentanil in-
fusion compared with baseline. None of the patients suffered 
from hypoxemia, desaturation, apnea, truncal rigidity, or other 
adverse effects. 
DISCUSSION
  This study demonstrated that when remifentanil was admini-
stered at target effect-site concentration of 5 ng/ml, pretreatment 
of intravenous ketamine 0.1 mg/kg reduced the incidence of 
remifentanil-induced cough from 27.9% to 11.5% (P ＜ 0.001). 
However, its severity and onset time was unaffected (P ＞ 0.05). 
  Several reports using different drugs have been recently pub-
lished to prevent the opioid-induced cough [1,5-9]. Most of 
them were on the fentanyl-induced cough. Although various 
mechanisms responsible for opioid-induced cough have been 
postulated, the exact mechanism is still unclear. Opioid could 
inhibit central sympathetic outflow, therefore activating the va-
gus nerve. This enhancement of vagal activity was reported as 
a possible cause of cough and reflex bronchoconstriction 
[7,11,12]. Other possible mechanisms postulated as the cause 
of opioid-induced cough include pulmonary chemoreflex, which 
is mediated by either rapidly adapting irritant receptors or va-
gal C-fiber receptors located in proximity to pulmonary vessels 
[13,14], and the trigger stimulus and bronchial hyperirritability 
theory [7,12]. 
  Ketamine is a noncompetitive NMDA receptor antagonist 
and NMDA receptor was suggested to be involved in regu-
lation of cough reflex [10]. Experimental studies have demon-
strated that remifentanil activated NMDA receptor but fentanyl 
did not [15,16]. The incidence of remifentanil-induced cough in 
this study was higher than that of fentanyl-induced cough 
(27.9% vs. 8% respectively) [2]. This higher incidence of 
cough with remifentanil may be explained by the difference in 
the stimulation of NMDA receptors. Ketamine may attenuate 
reflex bronchoconstriction or cough through the blockade of 
NMDA receptor activation, which result in the direct or in-
direct bronchodilating effects on airway smooth muscle [3,17]. 
Bongianni et al [18] reported in anesthetized rabbits that mi-
croinjection of NMDA receptor antagonists into the caudal part 
of ventral respiratory group suppressed the inspiratory and ex-
piratory components of cough reflex. Previous study using 
small dose lidocaine (0.5 mg/kg) reported that there was a sig-
nificant reduction in the incidence of cough (absolute risk re-
duction, 12.4%; relative risk reduction, 44.9%) [1]. In this 
study using 0.1 mg/kg of ketamine, the risk reduction was 
greater than the study with lidocaine since there was sig-
nificant reduction in the incidence rate of cough from 27.9% 
to 11.5% (absolute risk reduction, 16.4%; relative risk reduc-
tion, 60.4%). Ketamine was administered 1 min before re-
mifentanil infusion because ketamine has the rapid onset of ac-
tion with peak concentration occurring within 1 min after IV 
administration. The dose of ketamine (0.1 mg/kg) in this study 
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was based on a previous study by Yeh et al (0.15 mg/kg) [5]. 
The dose was reduced to decrease the side-effects of ketamine. 
  As for the hemodynamic effect of ketamine during anes-
thesia induction, there were significant differences in MAP and 
SpO2, but it was clinically insignificant because no patients 
had showed a MAP above 120 mm Hg or SpO2 ＜ 90%. 
Furthermore, MAP in ketamine group did not change 1 min 
after remifentanil infusion, whereas that in the saline group 
was significantly decreased. These results are consistent with a 
previous study by Koo et al [19]. 
  In conclusion, administration of IV ketamine 0.1 mg/kg one 
minute before remifentanil was effective in suppressing re-
mifentanil-induced cough without affecting the severity and on-
set time. 
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